Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J.-S.
Right arrow Articles by Waldman, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.-S.
Right arrow Articles by Waldman, T.
Vol. 1, 1355-1359, December 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Proof-of-Principle: Oncogenic ß-Catenin Is a Valid Molecular Target for the Development of Pharmacological Inhibitors 1

Jung-Sik Kim, Heather Crooks, Aaron Foxworth and Todd Waldman2

Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20057


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Activation of ß-catenin is a critical step in the pathogenesis of many common human cancers and is the initiating event in adenocarcinoma of the colon. Because activation of ß-catenin provides a gain-of-function, it is tempting to speculate that specific pharmacological inhibition of activated ß-catenin might reverse the tumorigenic properties of human cancer cells and therefore form the basis of an effective anticancer strategy. In an effort to provide proof-of-principle for such a strategy, we used a novel clonal growth assay based on human somatic cell gene targeting to determine whether activated ß-catenin remains a necessary oncogenic stimulus in advanced human cancer cells. Using this approach, we demonstrate that ß-catenin is a necessary oncogene in human SW48 and DLD1 colon cancer cells but not in HCT116 cells. These data indicate that activated ß-catenin can remain a critical oncogenic stimulus throughout the progression of human colon cancer and suggest that the small molecule inhibitors of activated ß-catenin currently under development will be effective anticancer therapeutics in a subset of malignant colon cancers.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Activation of the ß-catenin oncogene is critical to the pathogenesis of many common human cancers. ß-catenin can be activated either by intragenic mutations that abolish inhibitory phosphorylation sites or by extragenic mutations in its binding partners APC3 and Axin (1). Intragenic mutations in ß-catenin are found in a variety of human tumor types, including colon cancer, hepatocellular cancer, thyroid cancer, and endometrial cancer (2–5). Extragenic mutations in either APC or Axin are found in colon cancer, breast cancer, and hepatocellular cancer (6–8).

ß-catenin is a component of the Wnt signaling pathway (9). Normally, ß-catenin is found in two intracellular pools: bound to E-cadherin at the cell membrane, and in a complex with other proteins, including APC and Axin, in the cytoplasm. Activation of ß-catenin is thought to dramatically increase its stability and cause it to be translocated to the nucleus. Nuclear ß-catenin then binds to members of the TCF family of transcription factors. These heterodimers between a TCF (providing the DNA binding domain) and ß-catenin (providing the transcriptional activation domain) drive the transcription of Wnt target genes. Numerous candidate genes have been proposed as critical downstream effectors of Wnt signaling in cancer, including c-myc, cyclin D1, and BMP4 (10–13).

Oncogenes such as ß-catenin represent, at least in theory, extremely attractive molecular targets for the development of anticancer pharmaceuticals. There are several reasons for this. First, and very importantly, activation of ß-catenin is a gain-of-function. As such, it is feasible to use well-established techniques in drug development to develop inhibitors. Second, ß-catenin is activated in many common human cancers. Therefore, effective inhibitors of ß-catenin would be predicted to be broadly effective against a variety of common cancers. For these reasons, numerous academic laboratories and pharmaceutical companies are working to develop pharmacological inhibitors of activated ß-catenin with the hope that they will represent effective anticancer pharmaceuticals.

However, it has not yet been unambiguously demonstrated that specific inhibition of oncogenic ß-catenin can actually reverse the tumorigenic properties of human cancer cells. The technologies used to date have either simultaneously inhibited both the wild-type and activated forms of the protein (14, 15) or inactivated TCF4 instead, a protein thought to be functional surrogate for oncogenic ß-catenin (16, 17). As such, it has remained a possibility that although activation of ß-catenin is a critical initiating event in the pathogenesis of a human tumor, it eventually becomes superfluous in the face of additional mutations in other oncogenes and tumor suppressor genes. If this were true, pharmacological inhibition of oncogenic ß-catenin would be ineffective as a treatment for advanced human cancers.

To test whether complete, specific inhibition of oncogenic ß-catenin can reverse the transformed properties of human cancer cells, we used a novel clonal growth assay based on human somatic cell gene targeting. The assay is the converse of the well-accepted clonal growth assay that is commonly used to measure the growth-suppressing activity of transfected tumor suppressor genes, such as p53 (18). However, instead of measuring the reduction in colony number after the addition of an ectopically expressed tumor suppressor gene, our assay measures the clonal growth potential of cells after the subtraction of an endogenous activated oncogene. By applying this assay to three commonly studied colon cancer cell lines harboring activated ß-catenin, we demonstrate that oncogenic ß-catenin is required for clonal growth in a subset of human cancer cell lines. As such, we provide proof-of-principle that specific inhibition of oncogenic ß-catenin is a feasible strategy for the treatment of human cancer.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Creation of Human ß-Catenin-targeting Vectors.
ß-cateninKO-neo is a previously described high-efficiency human gene-targeting vector designed to delete ß-catenin exons II-IV and replace them with an in-frame promotorless neoR gene (13). ß-cateninKO-hyg is identical to ß-cateninKO-neo except that it contains a promotorless hygR gene instead of a promotorless neoR gene. It was created using an identical cloning strategy using homologous recombination in Saccharomyces cerevisiae.

Tissue Culture and Transfection.
SW48, HCT116, and DLD1 cells were obtained from the American Type Culture Collection (Manassas, VA) and grown in McCoy’s 5A media (Life Technologies, Inc., Carlsbad, CA) at 37°C in 5% CO2, in media containing 10% fetal bovine serum (Mediatech, Herndon, VA) and 1% penicillin-streptomycin (Life Technologies, Inc.).

To create heterozygous KOs in SW48 cells, ~20 25 cm2 flasks were transfected with Not I linearized ß-cateninKO-neo (New England BioLabs, Beverly, MA) using LipofectAMINE (Invitrogen, Carlsbad, CA), following the manufacturer’s protocol. Clones were selected in 0.3 mg/ml G418 for ~3 weeks, changing the media every 3 days. Each flask of pooled clones was then individually trypsinized, counted, and plated out at limiting dilution in 96-well plates to create individual clones. Clones were allowed to grow for ~3 weeks. Individual colonies were transferred first to wells in a 24-well plate, then to a 25 cm2 flask. Cells in confluent flasks were trypsinized, and approximately one-third of the cells was used for preparation of genomic DNA, whereas two-thirds were used for cryopreservation.

To create DLD1 heterozygous KO clones, cells were transfected with Not I-linearized ß-cateninKO-neo using LipofectAMINE (Invitrogen), following the manufacturer’s protocol. To obtain stably transfected clones by limiting dilution, cells were trypsinized ~18 h after transfection, mixed with media containing 1 mg/ml G418 (Invitrogen), and distributed to 96-well plates. After ~2 weeks of growth, individual colonies were transferred first to wells in a 24-well plate, then to a 25 cm2 flask. Cells in confluent flasks were trypsinized, and approximately one-third of the cells was used for preparation of genomic DNA, whereas two-thirds were used for cryopreservation.

In an effort to create DLD1 homozygous KO clones, several independently derived DLD1 heterozygous KO clones were transfected with ß-cateninKO-hyg, and individual hygR colonies were selected by limiting dilution in 0.2 mg/ml hygromycin B (Invitrogen) as described above. Cells in confluent flasks were trypsinized, and approximately one-third of the cells was used for preparation of genomic DNA, whereas two-thirds were used for cryopreservation.

Genomic PCR, Southern Blots, and DNA Sequencing.
Preparation of genomic DNA, PCR, Southern blots, and automated sequencing were all performed using standard techniques. Taq Platinum (Invitrogen) was used for PCR, according to the manufacturer’s instructions. For Southern blots, 5 µg of genomic DNA were digested with Sph I, separated on a 1% agarose gel, and transferred to a Zeta-Probe nylon membrane (Bio-Rad, Hercules, CA). The membrane was prehybridized overnight at 60°C, then hybridized for 24 h at 60°C using a radiolabelled, PCR-generated probe for ß-catenin intron VI. The blot was then washed and imaged using a Molecular Dynamics phosphorimager.

Xenograft Growth Assay.
Tumors were established by s.c. injection of 2 x 106 cells suspended in HBSS in the flanks of an immunodeficient mouse. Tumor growth rate was determined by measuring three orthogonal diameters of each tumor twice a week, and the tumor volume was estimated at {pi}/6 (D1D2D3).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Targeted Deletion of ß-Catenin in HCT116 Cells.
HCT116 cells were initially isolated from an invasive, metastatic colonic adenocarcinoma and harbor a common heterozygous activating mutation in ß-catenin, an in-frame deletion of serine 45 (2, 19). We described recently derivatives of HCT116 cells in which either the wild-type or mutant allele of ß-catenin had been deleted by gene targeting (13). The wild-type and mutant alleles were targeted with virtually equal frequency.

To determine whether deletion of the oncogenic allele of ß-catenin affected the malignant properties of HCT116 cells, we measured the ability of the parental cells and ß-catenin gene-targeted derivatives to grow in vitro and in vivo as xenografts in immunodeficient mice. HCT116 parental cells and several independently derived heterozygous KO clones lacking either wild-type ß-catenin or oncogenic ß-catenin displayed similar in vitro growth rates (data not shown). Strikingly, both the parental cells and two independently derived gene-targeted derivatives lacking oncogenic ß-catenin formed tumors with virtually complete efficiency (Figs. 1A and C), and the tumors grew at similar rates (in fact, the gene-targeted cells grew somewhat faster; Fig. 1B). These surprising data, which are similar to those reported recently by Chan et al. (20) and Sekine et al. (21), indicate that complete inhibition of oncogenic ß-catenin is insufficient to revert the transformed properties of HCT116 cells.



View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1. Xenograft growth of ß-catenin gene-targeted HCT116 cells. Two million cells of various ß-catenin genotypes were injected s.c. into the flanks of immunodeficient mice, and tumor formation and growth rate were monitored over a 3-week period. A, efficiency of tumor formation. +, a wild-type allele of ß-catenin; *, an oncogenic allele; KO, a targeted allele. B, tumor growth rate. •, parental cells (+/*); {blacksquare}, ß-catenin gene-targeted derivatives (+/KO). C, representative xenograft tumors on day 25 postinjection.

 
Targeted Deletion of ß-Catenin in DLD1 Cells.
We next attempted to confirm these surprising data acquired in HCT116 cells using a second cell system with a different mechanism of activation of ß-catenin. DLD1 cells were chosen for this, because they are a colon cancer cell line with activated ß-catenin by virtue of homozygous inactivating mutations of the APC tumor suppressor gene and are well established as being suitable for human somatic cell gene targeting (22, 23). Because in DLD1 cells, ß-catenin is activated by extragenic mutations in APC, it was necessary to delete both copies of ß-catenin to completely inhibit the activated form of ß-catenin.

Initially, DLD1 cells were transfected with ß-cateninKO-neo to create heterozygous KO cell lines, as described in "Materials and Methods." Individual geneticin-resistant colonies were obtained, expanded into clonal cell lines, tested by PCR, and confirmed by Southern blots to determine whether the targeting vector had integrated into the ß-catenin locus by homologous recombination (Fig. 2A). In 12 of 44 (27%) of the cell lines tested, the targeting vector had integrated via homologous recombination and deleted an allele of ß-catenin. These heterozygous KO cell lines were morphologically indistinguishable from parental DLD1 cells with two wild-type copies of ß-catenin.



View larger version (52K):
[in this window]
[in a new window]
  		Fig. 2. Gene targeting of activated ß-catenin in DLD1 cells. A, Southern blot analysis of DLD1 parental cells (Lane 1), gene-targeted clones obtained after transfection of DLD1 parental cells with ß-catenin KO-neo (Lanes 2–4), and gene-targeted clones obtained after transfection of heterozygous KO clones with ß-cateninKO-hyg (Lanes 5–7). The wild-type allele is 3 kb, the neo-targeted allele is 3.3 kb, and the hyg-targeted allele is 7.5 kb. B, list of DLD1 double KO clones.

 
Next, we attempted to delete the remaining allele of ß-catenin in the heterozygous KO cells. To do this, we modified the ß-cateninKO-neo-targeting vector by replacing the neoR gene with a hygR gene. Heterozygous KO cells were transfected with ß-cateninKO-hyg as described in "Materials and Methods." Individual hygromycin-resistant colonies were obtained, expanded into clonal cell lines, and tested via a Southern blot-based strategy to determine whether the targeting vector had integrated into the ß-catenin locus by homologous recombination (Fig. 2A). In 8 of 40 (20%) of the cell lines tested, the targeting vector had integrated via homologous recombination. In each of the eight gene-targeted cell lines tested, the targeting vector had integrated into the already targeted allele (Fig. 2B; examples in Fig. 2A, Lanes 5–7), indicating that homozygous deletion of activated ß-catenin is incompatible with clonal growth of the cells (P = 0.005).

These data demonstrated that complete inhibition of activated ß-catenin led to a reversal of the most fundamental transformed property of DLD1 cells: their ability to grow in vitro. However, definitive interpretation of these data were complicated by the fact that homozygous deletion of ß-catenin simultaneously removed both the wild-type and activated functions of the protein. It remained a distinct possibility that the oncogenic functions of ß-catenin were dispensable in DLD1 cells but that wild-type ß-catenin was simply an essential gene.

Targeted Deletion of ß-Catenin in SW48 Cells.
In an effort to reconcile these data, we decided to target oncogenic ß-catenin in a third cell line. SW48 cells were chosen because they are a near diploid human colon cancer cell line harboring a well-characterized heterozygous activating mutation of the ß-catenin oncogene (S33Y; Ref. 2). Therefore, as in the case of HCT116 cells, it is theoretically possible to specifically delete the activated form of ß-catenin while leaving the wild-type allele of ß-catenin intact.

SW48 cells were transfected with the ß-cateninKO-neo human promotorless targeting vector as described in "Materials and Methods." A group of 290 individual geneticin-resistant colonies was obtained, expanded into clonal cell lines, and tested by PCR to determine whether the targeting vector had integrated into the ß-catenin locus by homologous recombination (Fig. 3A). In 33 of 290 (11%) of the cell lines tested, the targeting vector had integrated via homologous recombination. To determine whether the wild-type or oncogenic allele had been deleted, the remaining untargeted allele was amplified by PCR and sequenced (Fig. 3B). In each of the 33 gene-targeted cell lines tested, the wild-type allele had been deleted, and the oncogenic allele was intact, indicating that specific deletion of the ß-catenin oncogene is incompatible with clonal growth of SW48 cells (P < 0.0001; examples in Fig. 3C). These data demonstrate that specific inhibition of the oncogenic form of ß-catenin leads to reversion of the in vitro growth properties of SW48 cells.



View larger version (40K):
[in this window]
[in a new window]
  		Fig. 3. Gene targeting of the human ß-catenin oncogene in SW48 cells. A, PCR-based identification of gene-targeted clones. Parental SW48 cells have a single 2.5-kb band derived from two untargeted alleles of ß-catenin. Heterozygous KO clones have a 2.5-kb band derived from the untargeted allele and a 1.8-kb band from the targeted allele. B, sequence-based identification of the untargeted allele. PCR products from the untargeted allele(s) were sequenced with an antisense primer to determine whether the untargeted allele was wild type (+) or mutant (*). In parental SW48 cells (+/*), the sequence diverges at serine 33 because the sequencing template is a mixture of wild-type and mutant ß-catenin genes. Gene-targeted clones in which the mutant, oncogenic allele remained are depicted as ko/*. C, list of representative targeted clones.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This is, to our knowledge, the first demonstration that specific inhibition of the oncogenic form of ß-catenin is sufficient to revert the transformed properties of human cancer cells. As such, we provide evidence that pharmacological inhibition of oncogenic ß-catenin is likely to be an effective strategy for reversing the malignant properties of advanced human tumors.

The fact that HCT116 cells are completely resistant to deletion of oncogenic ß-catenin suggests that a subset of cancers harboring activated ß-catenin will be resistant to small molecule inhibitors of activated ß-catenin. This resistance is likely because of the presence of additional mutations in other oncogenes or tumor suppressors that render the need for oncogenic ß-catenin as superfluous.

In addition to providing an important proof-of-principle, the results and reagents described herein provide several possible avenues for future ß-catenin-targeted anticancer drug discovery. First, the isogenic set of ß-catenin gene-targeted HCT116 cells studied here are potentially valuable as the basis of a cell-based screen for identifying small molecules that specifically kill cells harboring activated ß-catenin. Such compounds presumably would not inhibit activated ß-catenin directly but might instead modulate other important molecules that govern Wnt signaling. The advantage of such a cell-based screen is that it makes no assumptions regarding the biochemical function of active lead compounds; instead, it would identify in an unbiased way molecules that selectively kill cancer cells harboring activated ß-catenin. Second, it may be possible to validate inhibitors of ß-catenin identified in more conventional in vitro screens by testing their activities against a panel of SW48 and HCT116 cells. On the basis of the data described herein, compounds that inhibit the growth of SW48 cells, but not HCT116 cells, are good candidates as specific, effective inhibitors of activated ß-catenin.

In summary, we describe a novel clonal growth assay based on human somatic cell gene targeting and demonstrate that the ß-catenin oncogene is a necessary growth stimulus in a subset of human colon cancer cell lines. These results have significant relevance to understanding the function of activated ß-catenin in the pathogenesis of human cancer, and provide an important proof-of-principle guiding the development of anticancer pharmaceuticals.


   Acknowledgments
 
We thank Challice Bonifant for initial efforts to target ß-catenin in SW48 cells, Tagvor Nishanian and Carolyn Lee for their comments on this manuscript, Rebecca Slack for biostatistics consultation, and Henry Yang for expert assistance with DNA sequencing.


   Footnotes
 
1 Supported by NIH Grants K01 CA87828, R55 CA95736, and R01 CA095736 and the Lombardi Cancer Center Support Grant P30 CA51008. T.W. is a V Foundation Scholar and the recipient of a Career Development Award from the American Society of Clinical Oncology. Back

2 To whom requests for reprints should be addressed, at Lombardi Cancer Center, Georgetown School of Medicine, Research Building, Room E304, 3970 Reservoir Road, N.W., Washington, DC 20057. Phone: (202) 687-1340; Fax: (202) 687-7505; E-mail: waldmant{at}georgetown.edu Back

3 The abbreviations used are: APC, adenomatous polyposis coli; KO, knockout; TCF, T-cell factor. Back

Received 8/27/02; revised 10/28/02; accepted 10/30/02.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Polakis, P. Wnt signaling and cancer. Genes Dev., 14:1837 –1851,2000 .[Free Full Text]
  2. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. Activation of ß-catenin-Tcf signaling in colon cancer by mutations in ß-catenin or APC. Science (Wash. DC), 275:1787 –1790,1997 .[Abstract/Free Full Text]
  3. Miyoshi, Y., Iwao, K., Nagasawa, Y., Aihara, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., and Nakamura, Y. Activation of the ß-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 58:2524 –2527,1998 .[Abstract/Free Full Text]
  4. Garcia-Rostan, G., Tallini, G., Herrero, A., D’Aquila, T. G., Carcangiu, M. L., and Rimm, D. L. Frequent mutation and nuclear localization of ß-catenin in anaplastic thyroid carcinoma. Cancer Res., 59:1811 –1815,1999 .[Abstract/Free Full Text]
  5. Fukuchi, T., Sakamoto, M., Tsuda, H., Maruyama, K., Nozawa, S., and Hirohashi, S. ß-catenin mutation in carcinoma of the uterine endometrium. Cancer Res., 58:3526 –3528,1998 .[Abstract/Free Full Text]
  6. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., and Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis. Nature (Lond.), 359:235 –237,1992 .[CrossRef][Medline]
  7. Furuuchi, K., Tada, M., Yamada, H., Kataoka, A., Furuuchi, N., Hamada, J., Takahashi, M., Todo, S., and Moriuchi, T. Somatic mutations of the APC gene in primary breast cancers. Am. J. Pathol., 156:1997 –2005,2000 .[Abstract/Free Full Text]
  8. Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., Yamaoka, Y., and Nakamura, Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet., 24:245 –250,2000 .[CrossRef][Medline]
  9. Morin, P. J. ß-catenin signaling and cancer. Bioessays, 21:1021 –1030,1999 .[CrossRef][Medline]
  10. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Identification of c-MYC as a target of the APC pathway. Science (Wash. DC), 281:1509 –1512,1998 .[Abstract/Free Full Text]
  11. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., and Ben-Ze’ev, A. The cyclin D1 gene is a target of the ß-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA, 96:5522 –5527,1999 .[Abstract/Free Full Text]
  12. Tetsu, O., and McCormick, F. ß-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.), 398:422 –426,1999 .[CrossRef][Medline]
  13. Kim, J. S., Crooks, H., Dracheva, T., Nishanian, T. G., Singh, B., Jen, J., and Waldman, T. Oncogenic ß-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res., 62:2744 –2748,2002 .[Abstract/Free Full Text]
  14. Roh, H., Green, D. W., Boswell, C. B., Pippin, J. A., and Drebin, J. A. Suppression of ß-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res., 61:6563 –6568,2001 .[Abstract/Free Full Text]
  15. Shih, I. M., Yu, J., He, T. C., Vogelstein, B., and Kinzler, K. W. The ß-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res., 60:1671 –1676,2000 .[Abstract/Free Full Text]
  16. Naishiro, Y., Yamada, T., Takaoka, A. S., Hayashi, R., Hasegawa, F., Imai, K., and Hirohashi, S. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of ß-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res., 61:2751 –2758,2001 .[Abstract/Free Full Text]
  17. van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A. P., Tjon-Pon-Fong, M., Moerer, P., van den Born, M., Soete, G., Pals, S., Eilers, M., Medema, R., and Clevers, H. The ß-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell, 111:241 –250,2002 .[CrossRef][Medline]
  18. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Wash. DC), 249:912 –915,1990 .[Abstract/Free Full Text]
  19. Brattain, M. G., Fine, W. D., Khaled, F. M., Thompson, J., and Brattain, D. E. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res., 41:1751 –1756,1981 .[Abstract/Free Full Text]
  20. Chan, T. A., Wang, Z., Dang, L. H., Vogelstein, B., and Kinzler, K. W. Targeted inactivation of CTNNB1 reveals unexpected effects of ß-catenin mutation. Proc. Natl. Acad. Sci. USA, 99:8265 –8270,2002 .[Abstract/Free Full Text]
  21. Sekine, S., Shibata, T., Sakamoto, M., and Hirohashi, S. Targeted disruption of the mutant ß-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene, 21:5906 –5911,2002 .[CrossRef][Medline]
  22. Dexter, D. L., Barbosa, J. A., and Calabresi, P. N. N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res., 39:1020 –1025,1979 .[Abstract/Free Full Text]
  23. Sparks, A. B., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Mutational analysis of the APC/ß-catenin/Tcf pathway in colorectal cancer. Cancer Res., 58:1130 –1134,1998 .[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. Handeli and J. A. Simon
A small-molecule inhibitor of Tcf/{beta}-catenin signaling down-regulates PPAR{gamma} and PPAR{delta} activities
Mol. Cancer Ther., March 1, 2008; 7(3): 521 - 529.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. S. Shanmugam, H. Brenner, M. Hoffmeister, J. Chang-Claude, and B. Burwinkel
The functional genetic variant Arg324Gly of frizzled-related protein is associated with colorectal cancer risk
Carcinogenesis, September 1, 2007; 28(9): 1914 - 1917.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Bjorklund, G. Akerstrom, and G. Westin
Accumulation of Nonphosphorylated {beta}-Catenin and c-myc in Primary and Uremic Secondary Hyperparathyroid Tumors
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 338 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. K. Lee, Y. S. Choi, Y. A. Park, and S. Jeong
Modulation of Oncogenic Transcription and Alternative Splicing by {beta}-Catenin and an RNA Aptamer in Colon Cancer Cells
Cancer Res., November 1, 2006; 66(21): 10560 - 10566.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. H. Choi, M. W. Park, S. Y. Lee, M.-Y. Jeon, M. Y. Kim, H. K. Lee, J. Yu, H.-J. Kim, K. Han, H. Lee, et al.
Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer.
Mol. Cancer Ther., September 1, 2006; 5(9): 2428 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson
Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Endocr. Rev., December 1, 2005; 26(7): 898 - 915.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
C. Ngyuen, H. Ma, M. Eguchi, and M. Kahn
ICG-001, a Novel Chemogenomic Tool to Investigate the Wnt Pathway in Cancer
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 45 - 50.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Gail, R. Frank, and A. Wittinghofer
Systematic Peptide Array-based Delineation of the Differential {beta}-Catenin Interaction with Tcf4, E-Cadherin, and Adenomatous Polyposis Coli
J. Biol. Chem., February 25, 2005; 280(8): 7107 - 7117.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. H. Emami, C. Nguyen, H. Ma, D. H. Kim, K. W. Jeong, M. Eguchi, R. T. Moon, J.-L. Teo, S. W. Oh, H. Y. Kim, et al.
A small molecule inhibitor of {beta}-catenin/CREB-binding protein transcription
PNAS, August 24, 2004; 101(34): 12682 - 12687.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Su, S. Ishikawa, M. Kojima, and B. Liu
Eradication of pathogenic {beta}-catenin by Skp1/Cullin/F box ubiquitination machinery
PNAS, October 28, 2003; 100(22): 12729 - 12734.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J.-S.
Right arrow Articles by Waldman, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.-S.
Right arrow Articles by Waldman, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online